Skip to main content

Annexon Inc

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

ANNX$4.21-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included in the signature page hereto)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Douglas Love and Jennifer Lew his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Douglas Love, Esq.President, Chief Executive Officer and DirectorMarch 3, 2025
Douglas Love, Esq.(Principal Executive Officer)
/s/ Jennifer LewExecutive Vice President and Chief Financial OfficerMarch 3, 2025
Jennifer Lew(Principal Financial and Accounting Officer)
/s/ Thomas G. WiggansChairperson & DirectorMarch 3, 2025
Thomas G. Wiggans
/s/ William H. Carson, M.D.DirectorMarch 3, 2025
William H. Carson, M.D.
/s/ Jung E. ChoiDirectorMarch 3, 2025
Jung E. Choi
/s/ Bettina M. Cockroft, M.D.DirectorMarch 3, 2025
Bettina M. Cockroft, M.D.
/s/ William JonesDirectorMarch 3, 2025
William Jones
/s/ Muneer A. SatterDirectorMarch 3, 2025
Muneer A. Satter
/s/ William D. WaddillDirectorMarch 3, 2025
William D. Waddill
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.